|
|
Дата |
|---|
| 17.11.2026 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
| 04.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
10.00
|
10.17
|
10.51
|
9.71
|
10.8107
|
9.84
|
|
|
8 663 893.19
|
11 281.00
|
|
10.43
|
10.63
|
11.90
|
10.38
|
12.14
|
10.49
|
|
|
14 334 389.09
|
15 435.00
|
|
11.94
|
13.20
|
12.64
|
11.76
|
12.69
|
12.07
|
|
|
9 661 789.50
|
9 901.00
|
|
12.82
|
13.00
|
12.60
|
11.50
|
13.3299
|
12.57
|
|
|
20 172 137.25
|
17 597.00
|
|
13.33
|
14.15
|
14.00
|
13.48
|
14.00
|
13.49
|
|
|
6 212 904.97
|
7 211.00
|
|
13.62
|
14.49
|
14.00
|
13.60
|
14.55
|
13.78
|
|
|
7 384 865.94
|
8 298.00
|
|
13.93
|
14.32
|
13.25
|
12.93
|
14.43
|
14.18
|
|
|
9 398 273.26
|
8 467.00
|
|
12.90
|
13.29
|
12.90
|
12.47
|
13.17
|
13.06
|
|
|
8 172 901.02
|
8 699.00
|
|
12.40
|
13.00
|
14.00
|
12.455
|
14.11
|
12.57
|
|
|
16 617 574.71
|
14 736.00
|
|
13.90
|
14.35
|
14.27
|
13.40
|
14.34
|
14.16
|
|
|
8 936 482.55
|
8 962.00
|
Generate Biomedicines, Inc. is a clinical-stage generative biology company focusing on the Artificial intelligence (AI) revolution in biotechnology and drug design and development. The Company is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma.
Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.
Показать все Скрыть